Avenzo Therapeutics Reports Positive Preliminary Phase 1 Results for AVZO-1418 in Solid Tumors
Trendline

Avenzo Therapeutics Reports Positive Preliminary Phase 1 Results for AVZO-1418 in Solid Tumors

What's Happening? Avenzo Therapeutics, Inc. has announced positive preliminary clinical data from the Phase 1 portion of its AVENTINE-1 study, evaluating AVZO-1418, a bispecific EGFR/HER3 antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumors. The data, presented
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.